Paul Moss

TL;DR: Tetramers of human lymphocyte antigen A2 that were complexed with two different human immunodeficiency virus (HIV)-derived peptides or with a peptide derived from influenza A matrix protein bound to peptide-specific cytotoxic T cells in vitro and to T cells from the blood of HIV-infected individuals and correlated well with cytotoxicity assays.

TL;DR: Data implicate CMV as a major factor in driving oligoclonal expansions in old age and a dramatic accumulation of virus-specific effector CTL might impair the ability to respond to heterologous infection and may underlie the negative influence of CMV seropositivity on survival in the very elderly.

TL;DR: A novel approach to adoptive transfer of donor-derived CMV-specific CD8+ T cell clones has considerable potential for antigen-specific T cell therapy.

TL;DR: T cell immunity plays a central role in the control of SARS-CoV-2 and its importance may have been relatively underestimated thus far, and current COVID-19 vaccines elicit robust T cell responses that likely contribute to remarkable protection against hospitalization or death.

TL;DR: It is suggested that the selective and massive expansion of a few dominant clones of CD8+ T cells is an important feature of the primary response to this virus.